Arcturus Therapeutics (ARCT) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 50.0% versus a loss of 59.4%. Over five years, ARCT leads with a -76.8% price change compared with -85.3% for FULC. Arcturus Therapeutics is the larger company by market cap ($293.9 million vs $278.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | FULC |
|---|---|---|
| Share price | $10.34 | $3.65 |
| Market cap | $293.89M | $278.79M |
| 1-day change | -8.25% | -0.54% |
| YTD return | +68.68% | -67.73% |
| 1-year return | -49.95% | -59.40% |
| 5-year return | -76.77% | -85.26% |
| EPS (TTM) | $-3.33 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $0 |
| Revenue growth (YoY) | -46.14% | -100.00% |
| Net income (latest FY) | $-65.78M | $-74.88M |
| Operating margin | -92.96% | — |
| Net margin | -80.19% | — |
| 52-week high | $24.17 | $15.74 |
| 52-week low | $5.50 | $2.83 |
| Distance from 52-week high | -57.22% | -76.81% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +130.17% | +0.55% |
| Average volume | 941.87K | 1.52M |
| Shares outstanding | 28.42M | 76.38M |
| Employees | 106 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Arcturus Therapeutics grew revenue faster in its latest fiscal year (-46.14% vs -100.00%).
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ARCT vs FULC FAQ
Which is bigger, Arcturus Therapeutics or Fulcrum Therapeutics?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $293.89M compared with $278.79M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, ARCT or FULC?
ARCT returned -49.95% over the past 12 months, compared with -59.40% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.